Peptide Regulatory Status Tracker

At its July 23-24, 2026 meeting, FDA’s Pharmacy Compounding Advisory Committee voted on whether seven peptide-related substances should be added to the 503A bulk drug substances list. Per reports, it recommended BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, and did not recommend emideltide (DSIP). The vote is advisory; FDA had published no rule adding any of them as of October 19, 2026.

The committee voted on whether each substance, in free base and acetate forms, should be placed on the list of bulk drug substances that state-licensed 503A pharmacies may use in patient-specific compounding. Per AP reporting, the recommendation went against the conclusion of FDA's own staff scientists. Per McDermott Will & Schulte, FDA would next need notice-and-comment rulemaking, which could run into 2027 or later. Reported vote counts differ between sources and FDA has not published official tallies, so this table lists outcomes only.

It is an HHS/FDA notice titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94), received for White House OMB review on October 14, 2026. The filing gives no specifics. Per AP reporting, people familiar with the plan say it would let compounding pharmacies temporarily compound some peptides under FDA enforcement discretion. It had not been published as of October 19, 2026.

What the record shows, and what it does not:

• What was filed:per the reginfo.gov listing, an HHS/FDA item at the notice stage, titled "Interim Access Policy for Compounding Using Certain Peptides," received by OMB's Office of Information and Regulatory Affairs on October 14, 2026 and marked not economically significant.
• What it reportedly proposes: per AP reporting carried by CNBC and STAT on October 15, 2026, two people familiar with the plan said it is intended to let pharmacies temporarily compound some of the most popular peptides, including BPC-157, by assuring compounding pharmacies they will not be targeted, an approach known as enforcement discretion.
• Who it applies to: per the same reporting, compounding pharmacies. Nothing in the coverage describes it as applying to research-chemical sellers.
• What is not decided:which peptides are covered, for how long, and on what conditions. The filing gives no specifics. Formally adding peptides to FDA's list for compounding would still require rulemaking, and AP reported it was not clear whether the administration still plans to pursue that.

Per a LumaLex Law analysis, in mid-August 2026 Mississippi’s medical, nursing, and pharmacy boards and the South Carolina Board of Medical Examiners issued notices saying licensed providers may not compound, dispense, prescribe, supply, or recommend non-FDA-approved "research-grade" peptides to patients, and that patient consent forms do not change that.

Per the same analysis, the Mississippi statement says a provider may not delegate the purchase or dispensing of these products, among other listed activities, to other providers, and the South Carolina notice extends the prohibition to delegation to APRNs and PAs. Both notices say drugs and ingredients must be purchased from entities permitted by the state board of pharmacy. LumaLex Law notes that Alabama issued a similar notice on May 26, 2026, and characterizes all three as restating existing standards rather than creating new law. These are board notices, not statutes or rules.

FDA warning letters dated August 24, 2026 went to at least four online peptide sellers, stating that despite "research use only" labeling, evidence from the sellers’ websites establishes the products are intended to be drugs for human use. Per secondary coverage, FDA also issued a September 18, 2026 warning letter to a large 503A compounding pharmacy over compounded GLP-1 products. The full dated record is on the Amino Axiom FDA enforcement timeline.

The 2026 regulatory events tracked here are below. The full sequence back to 2020, including vendor closures and criminal cases, is on the FDA enforcement timeline.